Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$92.6 million.

  • Kymera Therapeutics' Income from Continuing Operations fell 2830.96% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 6593.79%. This contributed to the annual value of -$261.9 million for FY2024, which is 5802.23% down from last year.
  • Kymera Therapeutics' Income from Continuing Operations amounted to -$92.6 million in Q3 2025, which was down 2830.96% from -$84.7 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Income from Continuing Operations high stood at -$13.2 million for Q1 2021, and its period low was -$92.6 million during Q3 2025.
  • Its 5-year average for Income from Continuing Operations is -$49.6 million, with a median of -$44.9 million in 2022.
  • In the last 5 years, Kymera Therapeutics' Income from Continuing Operations surged by 4994.96% in 2023 and then tumbled by 31734.15% in 2024.
  • Kymera Therapeutics' Income from Continuing Operations (Quarter) stood at -$34.0 million in 2021, then decreased by 13.64% to -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then crashed by 317.34% to -$80.8 million in 2024, then decreased by 14.61% to -$92.6 million in 2025.
  • Its Income from Continuing Operations was -$92.6 million in Q3 2025, compared to -$84.7 million in Q2 2025 and -$74.5 million in Q1 2025.